Lexeo Therapeutics Inc
LXEO8.190USD
-0.230-2.73%
收盘 11/07, 16:00（美东）报价延迟15分钟
449.89M总市值
亏损市盈率 TTM
关于 Lexeo Therapeutics Inc 公司
Lexeo Therapeutics, Inc. 是一家临床阶段的基因医学公司，致力于通过应用开创性科学从根本上改变基因定义的心血管疾病和 APOE4 相关阿尔茨海默病的治疗方式，从而改变医疗保健。该公司采用分步开发方法，利用早期概念验证功能和生物标志物数据来推进心血管和 APOE4 相关阿尔茨海默病项目管线。其管线由针对患者群体的候选药物组成。其最先进的心血管候选产品 LX2006 用于治疗弗里德赖希共济失调 (FA) 心肌病患者，正在正在进行的 I/II 期临床试验 SUNRISE-FA 中进行评估。其第二先进的心血管候选产品 LX2020 用于治疗由 PKP2 基因突变 (PKP2-ACM) 引起的心律失常性心肌病，已获得美国食品药品监督管理局 (FDA) 的 IND 批准。
Lexeo Therapeutics Inc简介
公司代码LXEO
公司名称Lexeo Therapeutics Inc
上市日期Nov 03, 2023
CEOMr. R. Nolan Townsend
员工数量72
证券类型Ordinary Share
年结日Nov 03
公司地址345 Park Avenue South
城市NEW YORK
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编10010
电话12125479879
网址https://www.lexeotx.com/
公司代码LXEO
上市日期Nov 03, 2023
CEOMr. R. Nolan Townsend
Lexeo Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Louis Tamayo
Mr. Louis Tamayo
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
45.00K
--
Dr. Eric Adler, M.D.
Dr. Eric Adler, M.D.
Chief Medical Officer and Head of Research
Chief Medical Officer and Head of Research
11.04K
+127.67%
Dr. Jose Manuel Otero, Ph.D.
Dr. Jose Manuel Otero, Ph.D.
Chief Technical Officer
Chief Technical Officer
6.70K
+133.18%
Mr. Van Hauwermeiren
Mr. Van Hauwermeiren
Independent Director
Independent Director
--
--
Mr. Reinaldo M. Diaz
Mr. Reinaldo M. Diaz
Independent Director
Independent Director
--
--
Dr. Brenda Cooperstone, M.D.
Dr. Brenda Cooperstone, M.D.
Independent Director
Independent Director
--
--
Mr. R. Nolan Townsend
Mr. R. Nolan Townsend
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Paula H. J. Cholmondeley
Ms. Paula H. J. Cholmondeley
Independent Director
Independent Director
--
--
Ms. Mette Kirstine Agger
Ms. Mette Kirstine Agger
Independent Director
Independent Director
--
--
Dr. Steven M. (Steve) Altschuler, M.D.
Dr. Steven M. (Steve) Altschuler, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Louis Tamayo
Mr. Louis Tamayo
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
45.00K
--
Dr. Eric Adler, M.D.
Dr. Eric Adler, M.D.
Chief Medical Officer and Head of Research
Chief Medical Officer and Head of Research
11.04K
+127.67%
Dr. Jose Manuel Otero, Ph.D.
Dr. Jose Manuel Otero, Ph.D.
Chief Technical Officer
Chief Technical Officer
6.70K
+133.18%
Mr. Van Hauwermeiren
Mr. Van Hauwermeiren
Independent Director
Independent Director
--
--
Mr. Reinaldo M. Diaz
Mr. Reinaldo M. Diaz
Independent Director
Independent Director
--
--
Dr. Brenda Cooperstone, M.D.
Dr. Brenda Cooperstone, M.D.
Independent Director
Independent Director
--
--
收入明细
FY2023
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
暂无数据
地区USD
名称
营收
占比
United States
0.00
0.00%
业务
地区
暂无数据
股东统计
更新时间: 10月29日 周三
更新时间: 10月29日 周三
持股股东
股东类型
持股股东
持股股东
占比
RA Capital Management, LP
6.85%
Frazier Life Sciences Management, L.P.
6.06%
Balyasny Asset Management LP
5.49%
Janus Henderson Investors
5.05%
Citadel Advisors LLC
4.94%
其他
71.60%
持股股东
持股股东
占比
RA Capital Management, LP
6.85%
Frazier Life Sciences Management, L.P.
6.06%
Balyasny Asset Management LP
5.49%
Janus Henderson Investors
5.05%
Citadel Advisors LLC
4.94%
其他
71.60%
股东类型
持股股东
占比
Hedge Fund
29.93%
Investment Advisor/Hedge Fund
14.45%
Venture Capital
14.21%
Investment Advisor
8.03%
Private Equity
6.60%
Research Firm
3.41%
Individual Investor
0.51%
Bank and Trust
0.04%
Family Office
0.02%
其他
22.80%
机构持股
更新时间: 10月5日 周日
更新时间: 10月5日 周日
报告期
机构数
持股数
持股占比
持股变动
2025Q3
189
48.60M
66.59%
+5.10M
2025Q2
181
40.60M
122.31%
+231.62K
2025Q1
174
34.46M
103.80%
-3.48M
2024Q4
155
35.40M
107.08%
+416.99K
2024Q3
127
33.64M
101.76%
+2.87M
2024Q2
112
31.41M
96.45%
+1.88M
2024Q1
92
30.30M
97.67%
+5.87M
2023Q4
45
23.22M
87.68%
+3.57M
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Frazier Life Sciences Management, L.P.
4.42M
8.19%
--
--
Jun 30, 2025
Balyasny Asset Management LP
4.01M
7.42%
+4.01M
--
Jun 30, 2025
Janus Henderson Investors
3.68M
6.82%
-873.54K
-19.17%
Jun 30, 2025
Citadel Advisors LLC
3.61M
6.68%
+884.60K
+32.48%
Jun 30, 2025
Affinity Asset Advisors LLC
3.59M
6.65%
+2.11M
+142.38%
Jun 30, 2025
Vestal Point Capital, LP
3.23M
5.98%
+2.09M
+184.11%
Jun 30, 2025
Millennium Management LLC
2.84M
5.25%
+902.91K
+46.70%
Jun 30, 2025
Longitude Capital Management Co., LLC
2.77M
5.12%
--
--
Sep 30, 2024
Woodline Partners LP
2.57M
4.76%
+1.74M
+207.30%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.03%
iShares Micro-Cap ETF
0.03%
iShares Russell 2000 Value ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
查看更多
ProShares Ultra Nasdaq Biotechnology
占比0.04%
Invesco Nasdaq Biotechnology ETF
占比0.04%
iShares Biotechnology ETF
占比0.03%
iShares Micro-Cap ETF
占比0.03%
iShares Russell 2000 Value ETF
占比0.01%
ProShares UltraPro Russell2000
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
iShares Russell 2000 ETF
占比0.01%
Global X Russell 2000 ETF
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
